Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients
- PMID: 15684204
- DOI: 10.7326/0003-4819-142-3-200502010-00006
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients
Abstract
Background: The Pneumonia Severity Index (PSI) has been advocated as an objective measure of risk stratification to help determine the initial site of treatment for patients with community-acquired pneumonia.
Objective: To determine whether outpatient care of PSI-defined low-risk patients with community-acquired pneumonia is as safe and effective as hospitalization.
Design: Unblinded, randomized, controlled trial.
Setting: 2 tertiary care hospitals.
Patients: 224 immunocompetent adults in risk class II or III (PSI scores <or=90 points) who received a diagnosis of community-acquired pneumonia in the emergency department and had no extenuating circumstances.
Intervention: Outpatient care with oral levofloxacin therapy or hospitalization with sequential intravenous and oral levofloxacin therapy.
Measurements: The primary end point was the percentage of patients with an overall successful outcome at the end of treatment, according to 7 predefined criteria. Secondary end points included patients' quality of life and satisfaction.
Results: Overall successful outcome was achieved in 83.6% of outpatients and 80.7% of hospitalized patients (absolute difference, 2.9 percentage points [95% CI, -7.1 to 12.9 percentage points]). More outpatients were satisfied with their overall care (91.2% vs. 79.1%; absolute difference, 12.1 percentage points [CI, 1.8 to 22.5 percentage points]). Quality of life and the percentages of patients with adverse drug reactions (9.1% vs. 9.6%), medical complications (0.9% vs. 2.6%), subsequent hospital admissions (6.3% vs. 7.0%), and overall mortality (0.9% vs. 0%) were similar in the outpatient and hospitalization groups.
Limitations: The power to detect a serious complication, such as death, was limited given the relatively small sample size.
Conclusions: In selected patients who had community-acquired pneumonia, PSI risk class II and III, and were treated with levofloxacin, outpatient care in the absence of respiratory failure, unstable comorbid conditions, complicated pleural effusions, and social problems was as safe and effective as hospitalization and provided greater patient satisfaction.
Comment in
-
Summaries for patients. Can patients with pneumonia take their antibiotics at home?Ann Intern Med. 2005 Feb 1;142(3):I30. doi: 10.7326/0003-4819-142-3-200502010-00002. Ann Intern Med. 2005. PMID: 15684200 No abstract available.
-
Decisions about treating community-acquired pneumonia.Ann Intern Med. 2005 Feb 1;142(3):215-6. doi: 10.7326/0003-4819-142-3-200502010-00014. Ann Intern Med. 2005. PMID: 15684211 No abstract available.
Similar articles
-
Summaries for patients. Can patients with pneumonia take their antibiotics at home?Ann Intern Med. 2005 Feb 1;142(3):I30. doi: 10.7326/0003-4819-142-3-200502010-00002. Ann Intern Med. 2005. PMID: 15684200 No abstract available.
-
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.Clin Infect Dis. 2008 May 15;46(10):1499-509. doi: 10.1086/587519. Clin Infect Dis. 2008. PMID: 18419482 Clinical Trial.
-
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.Respir Med. 2006 Dec;100(12):2129-36. doi: 10.1016/j.rmed.2006.03.019. Epub 2006 May 26. Respir Med. 2006. PMID: 16730170 Clinical Trial.
-
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).J Chemother. 2004 Apr;16 Suppl 2:11-4. doi: 10.1080/1120009x.2004.11782367. J Chemother. 2004. PMID: 15255556 Review. No abstract available.
-
Levofloxacin in the treatment of community-acquired pneumonia.Expert Rev Anti Infect Ther. 2010 May;8(5):505-14. doi: 10.1586/eri.10.35. Expert Rev Anti Infect Ther. 2010. PMID: 20455679 Review.
Cited by
-
Early machine learning prediction of hospitalized patients at low risk of respiratory deterioration or mortality in community-acquired pneumonia: Derivation and validation of a multivariable model.Biomol Biomed. 2024 Mar 11;24(2):337-345. doi: 10.17305/bb.2023.9754. Biomol Biomed. 2024. PMID: 37795970 Free PMC article.
-
Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.Respir Res. 2022 Sep 10;23(1):239. doi: 10.1186/s12931-022-02117-3. Respir Res. 2022. PMID: 36088316 Free PMC article. Review.
-
Point-of-care application of diaphragmatic ultrasonography in the emergency department for the prediction of development of respiratory failure in community-acquired pneumonia: A pilot study.Front Med (Lausanne). 2022 Aug 17;9:960847. doi: 10.3389/fmed.2022.960847. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36059832 Free PMC article.
-
Comparison between the Severity Scoring Systems A-DROP and CURB-65 for Predicting Safe Discharge from the Emergency Department in Patients with Community-Acquired Pneumonia.Emerg Med Int. 2022 Apr 18;2022:6391141. doi: 10.1155/2022/6391141. eCollection 2022. Emerg Med Int. 2022. PMID: 35480967 Free PMC article.
-
Prevalence, Characteristics, and Outcomes of Emergency Department Discharge Among Patients With Sepsis.JAMA Netw Open. 2022 Feb 1;5(2):e2147882. doi: 10.1001/jamanetworkopen.2021.47882. JAMA Netw Open. 2022. PMID: 35142831 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical